Eli Lilly (LLY) announced that the FDA has approved the use of Synjardy (empagliflozin and metformin hydrochloride) tablets in treatment-naive adults with type 2 diabetes (T2D) as an adjunct to diet and exercise to improve glycemic control. The drug has been developed under the diabetes alliance between Eli Lilly and Boehringer Ingelheim, It is a combination of Jardiance (empagliflozin) and metformin.